LoQus23 is a DDF-formed company focussing on targeting DNA damage repair pathways to treat Huntington’s disease.
LoQus23 Therapeutics has raised €8.3M across 1 funding round from 2 investors, most recently a Seed round in Nov 2021. Based in London, UK; active in Healthtech. Data as of 7 Aug 2026.
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2021-11-23 | Seed | €8.3M |
| Dementia Discovery Fund,Novartis Venture Fund |
| View deal → |
